Hirohisa Yoshizawa

Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

Makoto Maemondo, Akira Inoue, Kunihiko Kobayashi et al. · New England Journal of Medicine · 2010 · 5.6K citations

Medicine, Oncology, Pharmacology +13

Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin–paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002)

Akira Inoue, Kunihiko Kobayashi, Makoto Maemondo et al. · Annals of Oncology · 2012 · 554 citations

Medicine, Oncology, Pharmacology +15

The burden of musculoskeletal conditions at the start of the new millennium

Julie Agel, Kristina Åkesson, Peter C. Amadio et al. · University of Twente Research Information · 2003 · 507 citations · Full text

Medicine, Orthopedic Surgery, Global Health +16

Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial

Mitsue Saito, Kenjiro Aogi, Ikuo Sekine et al. · The Lancet Oncology · 2009 · 434 citations

Medicine, Oncology, Pharmacology +14

Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: a retrospective analysis

Satoshi Watanabe, Junta Tanaka, Takeshi Ota et al. · BMC Cancer · 2011 · 394 citations · Full text

Medicine, Oncology, Pharmacotherapy +15